Literature DB >> 30247208

68Ga-Prostate-Specific Membrane Antigen PET/CT and 18F-FDG PET/CT of Primary Signet Ring Cell Breast Adenocarcinoma.

Ashwin Singh Parihar1, Bhagwant Rai Mittal1, Apurva Sood1, Rajender Kumar Basher1, Gurpreet Singh2.   

Abstract

Primary signet ring cell adenocarcinoma of the breast is a rare neoplasm. Similar to other mucinous neoplasms, it has low FDG avidity and poor prognosis compared with the traditional ductal/lobular carcinomas. We present a case of a 40-year-old woman with signet ring cell adenocarcinoma and skeletal fluorosis showing higher uptake of Ga-prostate-specific membrane antigen in the primary lesion and the metastatic sites compared with F-FDG on PET/CT imaging. Additionally, diffuse increased prostate-specific membrane antigen uptake was noticed in the entire skeleton, likely due to skeletal fluorosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30247208     DOI: 10.1097/RLU.0000000000002265

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  Nephrotoxicity after radionuclide therapies.

Authors:  Ashwin Singh Parihar; Sejal Chopra; Vikas Prasad
Journal:  Transl Oncol       Date:  2021-11-27       Impact factor: 4.243

2.  Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.

Authors:  Michele Balma; Virginia Liberini; Manuela Racca; Riccardo Laudicella; Matteo Bauckneht; Ambra Buschiazzo; Daniele Giovanni Nicolotti; Simona Peano; Andrea Bianchi; Giovanni Albano; Natale Quartuccio; Ronan Abgral; Silvia Daniela Morbelli; Calogero D'Alessandria; Enzo Terreno; Martin William Huellner; Alberto Papaleo; Désirée Deandreis
Journal:  Front Med (Lausanne)       Date:  2022-04-12

3.  Clinicopathological characteristics and survival in lung signet ring cell carcinoma: a population-based study.

Authors:  Yunting Cai; Yan Xie; Yanli Xiong; Wei Guan; Yu Pu; Dong Wang; Mingfang Xu; Shenglan Meng
Journal:  Bosn J Basic Med Sci       Date:  2021-12-01       Impact factor: 3.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.